Axon price target raised to $152 from $142 at Credit Suisse

Credit Suisse analyst Sami Badri raised the firm’s price target on Axon to $152 from $142 and keeps an Outperform rating on the shares. The company reported another solid quarter, posting revenues/Adjusted EBITDA of $311.8M/$67.8M, well above his estimates of $286.3M/$49.3M, achieving solid top-line growth along with margin expansion. Additionally, management raised the full year 2022 guidance again, revising up revenues guidance to $1.15B-$1.16B, representing a 34% year-over-year at mid-point, the fourth beat-raise since Q4, demonstrating how resilient Axon is amid economic slowdown concerns, Badri adds.